MX2022001704A - Metodos para tratar infecciones bacterianas. - Google Patents

Metodos para tratar infecciones bacterianas.

Info

Publication number
MX2022001704A
MX2022001704A MX2022001704A MX2022001704A MX2022001704A MX 2022001704 A MX2022001704 A MX 2022001704A MX 2022001704 A MX2022001704 A MX 2022001704A MX 2022001704 A MX2022001704 A MX 2022001704A MX 2022001704 A MX2022001704 A MX 2022001704A
Authority
MX
Mexico
Prior art keywords
methods
bacterial infections
treating bacterial
urinary tract
tract infection
Prior art date
Application number
MX2022001704A
Other languages
English (en)
Inventor
David C Griffith
Olga Lomovskaya
Jeffrey S Loutit
Michael N Dudley
Elizabeth E Morgan
Karen Fusaro
Original Assignee
Rempex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62791302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2022001704(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rempex Pharmaceuticals Inc filed Critical Rempex Pharmaceuticals Inc
Publication of MX2022001704A publication Critical patent/MX2022001704A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En la presente se describen métodos para tratar o mejorar una infección del tracto urinario (UTI), que incluye infección del tracto urinario complicada (cUTI) y pielonefritis aguda (AP), que comprenden administrar una composición que comprende un éster de ácido borónico cíclico, vaborbactam, en combinación con meropenem.
MX2022001704A 2017-01-09 2019-07-09 Metodos para tratar infecciones bacterianas. MX2022001704A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762444238P 2017-01-09 2017-01-09
US201762513936P 2017-06-01 2017-06-01

Publications (1)

Publication Number Publication Date
MX2022001704A true MX2022001704A (es) 2022-03-11

Family

ID=62791302

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019008281A MX2019008281A (es) 2017-01-09 2018-01-08 Metodos para tratar infecciones bacterianas.
MX2022001704A MX2022001704A (es) 2017-01-09 2019-07-09 Metodos para tratar infecciones bacterianas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019008281A MX2019008281A (es) 2017-01-09 2018-01-08 Metodos para tratar infecciones bacterianas.

Country Status (15)

Country Link
US (1) US20190336475A1 (es)
EP (2) EP4212157A1 (es)
JP (2) JP7436206B2 (es)
KR (1) KR20190104385A (es)
CN (1) CN110402139A (es)
AU (1) AU2018205327B2 (es)
BR (1) BR112019014089A2 (es)
CA (1) CA3048650A1 (es)
CL (2) CL2019001918A1 (es)
CO (1) CO2019008575A2 (es)
MX (2) MX2019008281A (es)
NZ (1) NZ755141A (es)
PH (1) PH12019501606A1 (es)
SG (1) SG11201906226YA (es)
WO (1) WO2018129479A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11376237B2 (en) * 2017-10-03 2022-07-05 Melinta Subsidiary Corp. Methods of treating bacterial infections
WO2024018372A2 (en) * 2022-07-20 2024-01-25 Sri Sathya Sai Institute Of Higher Learning A machine learning platform for predicting uropathogens and their resistance for prescribing suitable urinary infection therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
RS60310B1 (sr) 2010-08-10 2020-07-31 Rempex Pharmaceuticals Inc Ciklični derivati estra boronske kiseline, postupak za pripremu injihove terapeutske upotrebe
WO2014186309A1 (en) * 2013-05-15 2014-11-20 Schaeffler Technologies Gmbh & Co. Kg Reduced drag clutch plate
JP6945452B2 (ja) 2015-04-24 2021-10-06 レンペックス・ファーマシューティカルズ・インコーポレイテッド 細菌感染症の処置方法

Also Published As

Publication number Publication date
SG11201906226YA (en) 2019-08-27
PH12019501606A1 (en) 2020-06-15
CN110402139A (zh) 2019-11-01
JP2020504154A (ja) 2020-02-06
CL2019001918A1 (es) 2020-02-14
CL2020001886A1 (es) 2020-12-18
JP7436206B2 (ja) 2024-02-21
CO2019008575A2 (es) 2019-08-30
WO2018129479A1 (en) 2018-07-12
US20190336475A1 (en) 2019-11-07
KR20190104385A (ko) 2019-09-09
AU2018205327A1 (en) 2019-07-25
EP3565551B1 (en) 2024-03-20
MX2019008281A (es) 2019-12-02
EP3565551A4 (en) 2020-09-23
EP4212157A1 (en) 2023-07-19
NZ755141A (en) 2023-01-27
EP3565551A1 (en) 2019-11-13
BR112019014089A2 (pt) 2020-02-04
JP2023012538A (ja) 2023-01-25
CA3048650A1 (en) 2018-07-12
AU2018205327B2 (en) 2023-11-30

Similar Documents

Publication Publication Date Title
MX2016009898A (es) Tratamientos para acne resistente.
MX359921B (es) Métodos de tratamiento tópico para infecciones microbianas.
MX349827B (es) Compuestos que contienen nitrogeno y su uso.
AU2015205914B2 (en) 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections
WO2018115140A3 (en) Virulence attenuated bacteria based protein delivery
NZ713621A (en) Compounds and methods of treating infections
MX2018015184A (es) Métodos para el diagnóstico de infecciones bacterianas y virales.
MX2013006873A (es) Una composicion que comprende un agente antibiotico y un agente dispersante o un agente antiadhesivo.
MX2018001075A (es) Agentes terapeuticos y profilacticos antibacterianos.
MX2013012253A (es) Conjugados novedosos de aglutinante-farmaco (adc) y su uso.
MX350869B (es) Aceleracion de la recuperacion muscular despues de la atrofia muscular inducida por inmovilizacion.
NZ593111A (en) Antibacterial compounds
WO2012003474A3 (en) Compositions and methods related to protein a (spa) variants
GB201020860D0 (en) Disulfiram formulation and uses thereof
WO2010087964A3 (en) Compositions for treatment and prevention of acne, methods of making the compositions, and methods of use thereof
NZ603200A (en) Peptides and their use
PH12017501300A1 (en) Novel iodophor composition and methods of use
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
PH12019501606A1 (en) Methods of treating bacterial infections
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
CA3011003A1 (en) Bacterial ghosts for the treatment of cancer
WO2013162981A3 (en) Breast implant spacers for the treatment of periprosthetic breast implant infections
WO2011091154A3 (en) Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
MX2016004509A (es) Compuestos que contienen nitrogeno y su uso.
BR112012029262A2 (pt) métodos de tratamento de infecção bacteriana recorrente